MCY-M11

MaxCyte begins dosing in phase I solid tumors clinical trial
Pharmaceutical Business Review
Thu, 10/11/18 - 09:41 am
MaxCyte
MCY-M11
relapsed/refractory ovarian cancer
ovarian cancer
peritoneal mesothelioma
solid tumors